Description

Cinnarizin-OZ (Cinnarizinum) tablets 0.025 №50

Ingredients

Active ingredient: Cinnarizinum 0.025mg per tablet.

Dosage

Recommended dosage: The usual dose is 1 tablet taken 2-3 times daily with meals.

Indications

Cinnarizin-OZ tablets are indicated for the treatment of vertigo, Meniere’s disease, and motion sickness.

Contraindications

Do not use Cinnarizin-OZ tablets if you are allergic to cinnarizine or any other ingredients in the product. Consult your doctor before use if you are pregnant or breastfeeding.

Directions

Directions for use: Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Scientific Evidence

Cinnarizine, the active ingredient in Cinnarizin-OZ tablets, is a piperazine derivative that exerts its anti-vertigo effects through its calcium channel blocking properties. Studies have shown that cinnarizine is effective in reducing the frequency and severity of vertigo attacks in patients with Meniere’s disease.

Additional Information

Cinnarizin-OZ tablets have been well-tolerated in clinical trials, with common side effects including drowsiness and dry mouth. It is important to follow the recommended dosage and not exceed the prescribed amount to avoid adverse effects.

Pharmacological Effects: Cinnarizine acts by inhibiting the entry of calcium ions into smooth muscle cells, thereby preventing the constriction of blood vessels in the inner ear. This mechanism helps to improve blood flow and reduce symptoms of vertigo and dizziness.

Clinical Trials: A randomized controlled trial published in the Journal of Otolaryngology – Head & Neck Surgery demonstrated the efficacy of cinnarizine in reducing vertigo attacks and improving quality of life in patients with Meniere’s disease. The study concluded that cinnarizine is a safe and effective treatment option for vertigo associated with inner ear disorders.